SubQ vs. intramuscular, best sites for each compound, 8-zone rotation system, needle gauge selection, and step-by-step technique — everything needed to administer research peptides correctly.
Research Disclaimer: This guide covers injection technique for research purposes only. Research peptides are not FDA-approved for human use. All information is for laboratory and educational use.
The two primary injection routes for research peptides are subcutaneous (SubQ) and intramuscular (IM). The correct choice depends on the compound, the volume being administered, and the desired absorption profile. For the vast majority of research peptides, subcutaneous injection is the preferred route — it is easier to self-administer, requires shorter needles, produces more consistent pharmacokinetics, and causes less discomfort than intramuscular injection.
Injection into the fatty tissue layer beneath the skin, above the muscle. Slower, more sustained absorption due to lower blood flow in subcutaneous tissue.
Injection directly into muscle tissue. Faster, more complete absorption due to richer blood supply in muscle. Used for larger volumes or faster onset.
The five sites below cover the full range of subcutaneous and intramuscular injection locations used in research peptide protocols. Each is rated for ease of self-administration, absorption consistency, and rotation capacity.
Most recommended site for self-administration. Large surface area allows extensive rotation. Pinch a fold of skin before injecting.
Avoid: 2-inch radius around navel; scar tissue; waistband area
Outer lateral thigh (vastus lateralis) is a reliable SubQ and IM site. Use the middle third of the thigh. Alternate legs for rotation.
Avoid: Inner thigh (major vessels); back of thigh
Lateral deltoid area for SubQ. Harder to self-administer without a mirror. Good secondary rotation site.
Avoid: Deltoid muscle (IM only, not SubQ); inner arm (nerves, vessels)
Ventrogluteal site (hip bone area) is safer than dorsogluteal. Rarely needed for research peptides — most are SubQ. Requires proper landmark identification.
Avoid: Dorsogluteal site (near sciatic nerve) — use ventrogluteal instead
Good extension of the abdominal rotation zone. Consistent subcutaneous fat layer in most individuals. Alternate sides.
Avoid: Too far posterior (back muscles); over the kidney area
| Route | Gauge | Length | Syringe | Best For |
|---|---|---|---|---|
| SubQ (lean) | 29–31G | 5/16" (8mm) | 0.3–0.5mL insulin | Daily dosing, small volumes, lean physique |
| SubQ (standard) | 27–29G | 1/2" (12.7mm) | 0.5–1mL insulin | Most SubQ peptide protocols |
| SubQ (larger volume) | 25–27G | 1/2" (12.7mm) | 1mL insulin or standard | Volumes >0.5mL SubQ |
| IM (thigh) | 23–25G | 1" (25mm) | 1–3mL standard | IM injection into vastus lateralis |
| IM (glute) | 21–23G | 1–1.5" (25–38mm) | 1–3mL standard | IM injection into ventrogluteal site |
Systematic site rotation is the most important practice for preventing lipohypertrophy — the fibrous scar tissue buildup that impairs absorption and creates visible lumps. The 8-zone system below provides enough rotation capacity for daily dosing protocols while keeping each zone to a manageable, easy-to-remember location. Rotate through all 8 zones before returning to Zone 1.
Rotation tip: Keep a simple log (a sticky note on the vial, or a note on your phone) tracking which zone you used last. For daily dosing, rotate through all 8 zones over 8 days before returning to Zone 1 — this gives each site a full week of recovery.
| Compound | Preferred Site | Alternative | Notes |
|---|---|---|---|
| BPC-157 | SubQ (abdomen) | SubQ (thigh, flank) | Local SubQ near injury site is used in some protocols; systemic SubQ abdomen is most common |
| TB-500 (Thymosin Beta-4) | SubQ (abdomen) | SubQ (thigh) | Highly soluble; dissolves easily; systemic dosing preferred over local |
| CJC-1295 (with/without DAC) | SubQ (abdomen) | SubQ (thigh) | Pulse dosing before sleep; consistent SubQ site preferred for pharmacokinetic consistency |
| Ipamorelin | SubQ (abdomen) | SubQ (thigh) | Often co-administered with CJC-1295; same site acceptable for blend |
| Sermorelin | SubQ (abdomen) | IM (thigh) | FDA-approved Geref was IM; research protocols typically SubQ |
| Semaglutide / Tirzepatide | SubQ (abdomen) | SubQ (thigh, upper arm) | Matches FDA-approved injection sites for Ozempic/Wegovy/Mounjaro/Zepbound |
| Retatrutide | SubQ (abdomen) | SubQ (thigh) | TRIUMPH trial protocol used SubQ abdomen; weekly dosing allows full rotation |
| PT-141 (Bremelanotide) | SubQ (abdomen) | SubQ (thigh) | FDA-approved Vyleesi uses SubQ abdomen; 45 min before use in clinical protocol |
| GHK-Cu | SubQ (abdomen) | Topical (for skin applications) | Systemic SubQ for research; topical peptide serums for skin-specific applications |
| Epithalon | SubQ (abdomen) | IM (thigh) | Short tetrapeptide; SubQ is standard; some protocols use IM for faster absorption |
| MOTS-c | SubQ (abdomen) | SubQ (thigh) | Mitochondria-derived peptide; SubQ standard; rotate carefully for frequent dosing |
| Melanotan II / MT-2 | SubQ (abdomen) | SubQ (thigh) | SubQ standard; nausea is common side effect — lower dose first injection recommended |
Wash hands with soap and water for at least 20 seconds before handling any injection supplies. This is the single most effective contamination prevention step.
Reconstituted peptide vial, insulin syringe (appropriate gauge and length), alcohol swabs, clean surface or sterile pad. Confirm the peptide solution is clear and within its expiration window.
Choose the next site in your rotation sequence. Wipe the skin with an alcohol swab using a circular motion from center outward. Allow to air dry for 10–15 seconds — wet alcohol stings and can carry bacteria into the puncture site.
Swab the vial stopper with a fresh alcohol swab. Draw slightly more than your target volume into the syringe, then expel air bubbles and adjust to the exact dose. Confirm the volume against your calculated draw amount.
For subcutaneous injection, pinch a fold of skin between thumb and forefinger to elevate the subcutaneous layer away from the muscle. This is especially important for leaner individuals or shorter needles.
For SubQ: insert at 45–90 degrees depending on body composition and needle length (see needle selection table). For IM: insert at 90 degrees. Insert with a smooth, confident motion — hesitation increases discomfort.
Depress the plunger slowly and steadily over 5–10 seconds. Rapid injection increases discomfort and can cause tissue trauma. If you feel significant resistance, the needle may be in the wrong layer — withdraw and reposition.
Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab for 10–15 seconds. Do not rub — rubbing can cause bruising and disperse the compound away from the intended site.
Place the used needle immediately into a sharps container. Never recap needles with two hands. Never reuse needles — even a single use dulls the tip and increases injection trauma on subsequent use.
Record which rotation zone you used. This takes 5 seconds and prevents the most common cause of injection site problems — inadvertent repeat injection into the same spot.
Purgo Labs supplies lyophilized peptides with ≥99% purity, independent HPLC + mass spectrometry COAs, and cold chain shipping. Use code HEALTH for 15% off.
Subcutaneous (SubQ) injection delivers the compound into the fatty tissue layer just beneath the skin, above the muscle. The absorption rate is slower and more sustained because the subcutaneous layer has less blood flow than muscle tissue. Intramuscular (IM) injection delivers the compound directly into muscle tissue, which has a richer blood supply and produces faster, more complete absorption. For most research peptides, subcutaneous injection is preferred because it produces more consistent pharmacokinetics, is less painful, and requires shorter needles. Intramuscular injection is occasionally used for larger volumes or when faster absorption is desired.
For subcutaneous injection of research peptides, a 27–31 gauge needle is standard. Finer gauges (29–31G) cause less tissue trauma and are preferred for frequent dosing. Length should be 1/2 inch (12.7mm) or shorter for most subcutaneous sites — 5/16 inch (8mm) is sufficient for most individuals. Insulin syringes (100-unit, 0.5mL or 1mL) are the most common choice because they combine a fine gauge needle with precise volume markings. The needle length needed varies slightly based on body composition — leaner individuals may need shorter needles to avoid inadvertent intramuscular injection.
Injection sites should be rotated with every dose. Repeated injection into the same spot causes lipohypertrophy — a buildup of fibrous scar tissue in the subcutaneous layer — which impairs absorption and creates visible lumps under the skin. A systematic rotation pattern (e.g., clockwise around the abdomen, alternating sides) ensures each site gets adequate recovery time. As a general rule, do not inject into the same spot more than once every 7–10 days. Maintaining a simple log of injection sites makes systematic rotation easier.
The abdomen is the preferred subcutaneous injection site for most research peptides for several reasons: it has a consistent, accessible subcutaneous fat layer in most individuals; it is easy to self-administer without assistance; it provides a large surface area for rotation; and it produces reliable, consistent absorption kinetics. The recommended zone is the area between the navel and the hip bones, avoiding a 2-inch radius around the navel itself (which has denser connective tissue and more nerve endings). The outer flanks (love handle area) are also acceptable and provide additional rotation sites.
You should wait at least 7–10 days before reinjecting the same site. Repeated injection into the same location causes local tissue trauma, inflammation, and eventually lipohypertrophy — a hardened, fibrous lump that impairs absorption. If you notice a firm lump at a previous injection site, avoid that area entirely until it resolves, which typically takes several weeks. Systematic site rotation is the most effective prevention strategy.
If you aspirate before injecting and see blood in the syringe, withdraw the needle, apply gentle pressure with a clean swab, and select a new site. If you inject without aspirating and notice unusual burning, rapid heartbeat, or taste/smell changes immediately after injection, these may indicate intravascular injection — apply pressure to the site and monitor. For subcutaneous injections with short (1/2 inch or less) needles, intravascular injection is rare because the needle does not reach the depth of major blood vessels. However, aspiration before injection is still considered good practice.
For most subcutaneous research peptides, the injection site has minimal effect on efficacy as long as the injection is correctly placed in the subcutaneous layer. Absorption rates vary slightly between sites — the abdomen generally produces faster absorption than the thigh, which is faster than the upper arm — but these differences are modest for most compounds. The more important factors are consistent depth (subcutaneous, not intradermal or intramuscular), consistent rotation to prevent lipohypertrophy, and proper reconstitution and storage of the peptide itself.
For subcutaneous injection, the needle should be inserted at a 45–90 degree angle depending on body composition and needle length. For individuals with less subcutaneous fat (leaner physique), a 45-degree angle reduces the risk of inadvertently reaching the muscle layer. For individuals with more subcutaneous fat, a 90-degree angle is acceptable and often easier to execute consistently. With short insulin needles (5/16 inch or 8mm), a 90-degree angle is generally safe for most individuals. Pinching a fold of skin before inserting the needle helps ensure the injection stays in the subcutaneous layer.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.